TY - JOUR
T1 - Endocrine and local control of the primate corpus luteum
AU - Stouffer, Richard L.
AU - Bishop, Cecily V.
AU - Bogan, Randy L.
AU - Xu, Fuhua
AU - Hennebold, Jon D.
N1 - Funding Information:
The authors’ research as summarized in this review was supported by several federal ( NIH, USA ) grants, including R01 HD020869 (to R.L.S.), R01 HD042000 (to J.D.H.), NICHD-Supported Cooperative Research Centers in Infertility and Reproduction (SCCPIR U54 HD018185 ) and Contraceptive Development and Research (CDRC U54 HD055744 ), plus a research contract from Schering Female AMPPA (now Bayer Schering Pharma AG, Berlin, Germany). All animals and facilities for animal research were provided by ONPRC (P51 OD011092). Two Fellows (C.V.B., R.L.B.) received federal training grant support (T32 HD007133).
PY - 2013/12
Y1 - 2013/12
N2 - The primate corpus luteum is a transient endocrine gland that differentiates from the ovulatory follicle midway through the ovarian (menstrual) cycle. Its formation and limited lifespan is critical for fertility, as luteal-derived progesterone is the essential steroid hormone required for embryo implantation and maintenance of intra-uterine pregnancy until the placenta develops. It is well-established that LH and the LH-like hormone, CG, are the vital luteotropic hormones during the menstrual cycle and early pregnancy, respectively. Recent advances, particularly through genome analyses and cellular studies, increased our understanding of various local factors and cellular processes associated with the development, maintenance and repression of the corpus luteum. These include paracrine or autocrine factors associated with angiogenesis (e.g., VEGF), and that mediate LH/CG actions (e.g., progesterone), or counteract luteotropic effects (i.e., local luteolysis; e.g., PGF2α). However, areas of mystery and controversy remain, particularly regarding the signals and events that initiate luteal regression in the non-fecund cycle. Novel approaches capable of gene "knockdown" or amplification", in vivo as well as in vitro, should identify novel or underappreciated gene products that are regulated by or modulate LH/CG actions to control the functional lifespan of the primate corpus luteum. Further advances in our understanding of luteal physiology will help to improve or control fertility for purposes ranging from preservation of endangered primate species to designing novel ovary-based contraceptives and treating ovarian disorders in women.
AB - The primate corpus luteum is a transient endocrine gland that differentiates from the ovulatory follicle midway through the ovarian (menstrual) cycle. Its formation and limited lifespan is critical for fertility, as luteal-derived progesterone is the essential steroid hormone required for embryo implantation and maintenance of intra-uterine pregnancy until the placenta develops. It is well-established that LH and the LH-like hormone, CG, are the vital luteotropic hormones during the menstrual cycle and early pregnancy, respectively. Recent advances, particularly through genome analyses and cellular studies, increased our understanding of various local factors and cellular processes associated with the development, maintenance and repression of the corpus luteum. These include paracrine or autocrine factors associated with angiogenesis (e.g., VEGF), and that mediate LH/CG actions (e.g., progesterone), or counteract luteotropic effects (i.e., local luteolysis; e.g., PGF2α). However, areas of mystery and controversy remain, particularly regarding the signals and events that initiate luteal regression in the non-fecund cycle. Novel approaches capable of gene "knockdown" or amplification", in vivo as well as in vitro, should identify novel or underappreciated gene products that are regulated by or modulate LH/CG actions to control the functional lifespan of the primate corpus luteum. Further advances in our understanding of luteal physiology will help to improve or control fertility for purposes ranging from preservation of endangered primate species to designing novel ovary-based contraceptives and treating ovarian disorders in women.
KW - LH-CG
KW - Luteinization
KW - Luteolysis
KW - Luteolytic factors
KW - Luteotropic factors
UR - http://www.scopus.com/inward/record.url?scp=84888248596&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888248596&partnerID=8YFLogxK
U2 - 10.1016/j.repbio.2013.08.002
DO - 10.1016/j.repbio.2013.08.002
M3 - Review article
C2 - 24287034
AN - SCOPUS:84888248596
SN - 1642-431X
VL - 13
SP - 259
EP - 271
JO - Reproductive biology
JF - Reproductive biology
IS - 4
ER -